Physician profile
David O Sobel
NPI 1730181173
$397.34
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $164 · 2021: $39.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.50 | 2019 | |
| Merck Sharp & Dohme LLC | $41.71 | 2019-2020 | |
| Glaxosmithkline, LLC. | $29.80 | 2020-2021 | |
| Allergan, INC. | $29.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.34 | 2019 | |
| Zyla Life Sciences, INC. | $16.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2019 | |
| Abbvie INC. | $11.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.